(If you thought the first three quarters losses were large, wait until you see Q4.)
Orexo dumped the loser on Galena. Ahn bought it to pump the stock and then he dumped.
Baggies were fleeced and will take a bath on this Pump & Dump stock.
The DreamTeam pumped big numbers for Abstral but the reality is that Abstral will produce big losses.
"The reality of launching drugs in healthcare
I would like to share with you something that I think is truly telling about product launches in biotechnology, which are facts surrounding recent product launches.
Last December, Amarin Corporation (NASDAQ: AMRN) raised $100 million to assist in the launch of Vascepa. During its most recent quarter, the company spent almost $65 million to aid in Vascepa’s launch. As a result, the company earned $2.34 million in revenue during those initial months. During the last year, shares of Amarin Corporation have declined 60% showing its performance post-approval.
ARIAD Pharmaceuticals (NASDAQ: ARIA) launched its new drug Iclusig in the first quarter, a drug that treats a form of leukemia. This promising drug, that many believe could achieve annual sales in excess of $1 billion, produced just $6.1 million in its first quarter post-launch. Much like Amarin, the company spent a large deal of money to earn its sales, more than $70 million last quarter.
Vivus (NASDAQ: VVUS) has had its weight loss product, Qsymia, on the market for the last two quarters. During that period, Vivus has earned just $6 million and has spent more than $115 million. Over the last year, shares of this stock have declined 55%."
This is partly fantasy. You can not compare AMRN, ARIAD and Vivus launch of new products with Abstral. Thats just comparing apples and bananas.
Abstral is expected to be cash flow positive in h2 2014.
Appreciate you taking the time out to inform us poor stupid investors that can't really think for ourselves and rely on YMB d-bags for info. I shall sell my position in the AM like you suggested. Thanks friend!
Your comparing apples to oranges. Abstral is a successful drug in europe where they take drugs seriously.
It's established and has a following. People in the US have relatives in europe. Alot of products have success in the US that started in europe. Europe the leader in advanced medicine and therapies.
The fact that it acts quickly and is sublingual gives it an immense advantage, as many companies are going sublingual. Your stomach acid destroys alot of product going into your system and if you have a bad digestive system you could get too much or to little of product. Sublingual goes directly into the blood stream and is quicker and more acurate!!
Sentiment: Strong Buy
I hope you didn't take the DreamTeam pumps seriously.
Europe and the Us markets are different with different competitors and different competing drugs.
Europe is the leader? Who told you that, the DreamTeam?
Everything you wrote is pure BS.